Somatostatin analog and pegvisomant combination therapy for acromegaly

Nature Reviews Endocrinology

Volumn 5, Issue 10, 2009, Pages 546-552

  Neggers, Sebastian J C ^a   Van Der Lely, Aart Jan ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

PEGVISOMANT; SOMATOMEDIN C; SOMATOSTATIN DERIVATIVE;

ACROMEGALY; CHOLESTATIC HEPATITIS; COMBINATION CHEMOTHERAPY; DIABETES MELLITUS; DRUG EFFICACY; DRUG SAFETY; GLUCOSE METABOLISM; GROWTH HORMONE BLOOD LEVEL; HUMAN; HYPOPHYSIS TUMOR; LIPODYSTROPHY; LIVER CELL DAMAGE; PRIORITY JOURNAL; QUALITY OF LIFE; REVIEW; SIDE EFFECT; TUMOR VOLUME;

ACROMEGALY; DRUG THERAPY, COMBINATION; HUMAN GROWTH HORMONE; HUMANS; SOMATOSTATIN; TRANSAMINASES;

EID: 70349575206     PISSN: 17595029     EISSN: 17595037     Source Type: Journal    
DOI: 10.1038/nrendo.2009.175     Document Type: Review

References (39)

1. Melmed, S. Medical progress: acromegaly. N. Engl. J. Med. 355, 2558-2573 (2006).
2. Bates, P. R., Carson, M. N., Trainer, P. J., wass, J. A. & UK National Acromegaly Register Study Group (UKAR-2). wide variation in surgical outcomes for acromegaly in the UK. Clin. Endocrinol. (Oxf.) 68, 136-142 (2008).
3. Holdaway, I. M. Treatment of acromegaly. Horm. Res. 62 (Suppl. 3), 79-92 (2004).
4. Feenstra, J. et al. Combined therapy with somatostatin analogues and weekly pegvisomant in active acromegaly. Lancet 365, 1644-1646 (2005).
5. Neggers, S. J., de Herder, w. w., Janssen, J. A., Feelders, R. A. & van der Lely, A. J. Combined treatment for acromegaly with long-acting somatostatin analogues and pegvisomant: longterm safety up to 4.5 years (median 2.2 years) of follow-up in 86 patients. Eur. J. Endocrinol. 160, 529-533 (2009).
6. Neggers, S. J. et al. Long-term efficacy and safety of combined treatment of somatostatin analogs and pegvisomant in acromegaly. J. Clin. Endocrinol. Metab. 92, 4598-4601 (2007).
7. van der Lely, A. J. et al. Long-term treatment of acromegaly with pegvisomant, a growth hormone receptor antagonist. Lancet 358, 1754-1759 (2001).
8. Higham, C., Chung, T., Lawrance, J., Drake, w. & Trainer, P. Long term experience of pegvisomant therapy as a treatment for acromegaly. Clin. Endocrinol. (Oxf.) doi:10.1111/j.1365-22652008. 03469.x.).
9. Biering, H. et al. Elevated transaminases during medical treatment of acromegaly: a review of the German pegvisomant surveillance experience and a report of a patient with histologically proven chronic mild active hepatitis. Eur. J. Endocrinol. 154, 213-220 (2006).
10. Jørgensen, J. O. et al. Cotreatment of acromegaly with a somatostatin analog and a growth hormone receptor antagonist. J. Clin. Endocrinol. Metab. 90, 5627-5631 (2005).
11. Harris, P. E. Treatment with pegvisomant alone compared to combination therapy with pegvisomant/octreotide LAR, in acromegaly [OR53-3]. Presented at The Endocrine Society 89th Annual Meeting.).
12. Neggers, S. J. et al. Quality of life in acromegalic patients during long-term somatostatin analog treatment with and without pegvisomant. J. Clin. Endocrinol. Metab. 93, 3853-3859 (2008).
13. Kopchick, J. J., Parkinson, C., Stevens, E. C. & Trainer, P. J. Growth hormone receptor antagonists: discovery, development, and use in patients with acromegaly. Endocr. Rev. 23, 623-646 (2002).
14. Clark, R. et al. Long-acting growth hormones produced by conjugation with polyethylene glycol. J. Biol. Chem. 271, 21969-21977 (1996).
15. Drake, w. M., Parkinson, C., Besser, G. M. & Trainer, P. J. Clinical use of a growth hormone receptor antagonist in the treatment of acromegaly. Trends Endocrinol. Metab. 12, 408-413 (2001). (Pubitemid 33714238)
16. van der Lely, A. J. et al. Control of tumor size and disease activity during cotreatment with octreotide and the growth hormone receptor antagonist pegvisomant in an acromegalic patient. J. Clin. Endocrinol. Metab. 86, 478-481 (2001).
17. Leung, K. C., Doyle, N., Ballesteros, M., waters, M. J. & Ho, K. K. Insulin regulation of human hepatic growth hormone receptors: divergent effects on biosynthesis and surface translocation. J. Clin. Endocrinol. Metab. 85, 4712-4720 (2000).
18. Murray, R. D. et al. Central and peripheral actions of somatostatin on the growth hormone-IGF-I axis. J. Clin. Invest. 114, 349-356 (2004).
19. wurzburger, M. I., Prelevic, G. M., Sönksen, P. H., Balint-Peric, L. A. & wheeler, M. The effect of recombinant human growth hormone on regulation of growth hormone secretion and blood glucose in insulin-dependent diabetes. J. Clin. Endocrinol. Metab. 77, 267-272 (1993).
20. Shishko, P. I., Dreval, A. v., Abugova, I. A., Zajarny, I. U. & Goncharov, v. C. Insulin-like growth factors and binding proteins in patients with recent-onset type 1 (insulin-dependent) diabetes mellitus: influence of diabetes control and intraportal insulin infusion. Diabetes Res. Clin. Pract. 25, 1-12 (1994).
21. Petrossians, P. et al. Gross total resection or debulking of pituitary adenomas improves hormonal control of acromegaly by somatostatin analogs. Eur. J. Endocrinol. 152, 61-66 (2005).
22. Parkinson, C. et al. A comparison of the effects of pegvisomant and octreotide on glucose, insulin, gastrin, cholecystokinin, and pancreatic polypeptide responses to oral glucose and a standard mixed meal. J. Clin. Endocrinol. Metab. 87, 1797 - 1804 (2002).
23. De Marinis, L. et al. Long-term effects of the combination of pegvisomant with somatostatin analogs (SSA) on glucose homeostasis in nondiabetic patients with active acromegaly partially resistant to SSA. Pituitary 10, 227-232 (2007).
24. Beauregard, C., Truong, U., Hardy, J. & Serri, O. Long-term outcome and mortality after transsphenoidal adenomectomy for acromegaly. Clin. Endocrinol. (Oxf.) 58, 86-91 (2003).
25. Holdaway, I. M., Bolland, M. J. & Gamble, G. D. A meta-analysis of the effect of lowering serum levels of GH and IGF-I on mortality in acromegaly. Eur. J. Endocrinol. 159, 89-95 (2008).
26. Holdaway, I. M., Rajasoorya, C. R., Gamble, G. D. & Stewart, A. w. Long-term treatment outcome in acromegaly. Growth Horm. IGF Res. 13, 185-192 (2003).
27. Holdaway, I. M., Rajasoorya, R. C. & Gamble, G. D. Factors influencing mortality in acromegaly. J. Clin. Endocrinol. Metab. 89, 667-674 (2004).
28. Swearingen, B. et al. Long-term mortality after transsphenoidal surgery and adjunctive therapy for acromegaly. J. Clin. Endocrinol. Metab. 83, 3419-3426 (1998).
29. Hua, S. C., Yan, Y. H. & Chang, T. C. Associations of remission status and lanreotide treatment with quality of life in patients with treated acromegaly. Eur. J. Endocrinol. 155, 831-837 (2006).
30. Biermasz, N. R., Pereira, A. M., Smit, J. w., Romijn, J. A. & Roelfsema, F. Morbidity after long-term remission for acromegaly: persisting joint-related complaints cause reduced quality of life. J. Clin. Endocrinol. Metab. 90, 2731-2739 (2005).
31. Biermasz, N. R. et al. Decreased quality of life in patients with acromegaly despite long-term cure of growth hormone excess. J. Clin. Endocrinol. Metab. 89, 5369-5376 (2004).
32. Bonapart, T. I. et al. The 'bio-assay' quality of life might be a better marker of disease activity in acromegalic patients than serum total IGF-I concentrations. Eur. J. Endocrinol. 152, 217-224 (2005).
33. webb, S. M. et al. Acromegaly Quality of Life Questionnaire (AcroQoL) a new health-related quality of life questionnaire for patients with acromegaly: development and psychometric properties. Clin. Endocrinol. (Oxf.) 57, 251-258 (2002).
34. Schreiber, I. et al. Treatment of acromegaly with the GH receptor antagonist pegvisomant in clinical practice: safety and efficacy evaluation from the German Pegvisomant Observational Study. Eur. J. Endocrinol. 156, 75-82 (2007).
35. Shi, Y. F., Zhu, X. F., Harris, A. G., Zhang, J. X. & Dai, Q. Prospective study of the long-term effects of somatostatin analog (octreotide) on gallbladder function and gallstone formation in Chinese acromegalic patients. J. Clin. Endocrinol. Metab. 76, 32-37 (1993).
36. Feenstra, J., van Aken, M. O., de Herder, w. w., Feelders, R. A. & van der Lely, A. J. Drug-induced hepatitis in an acromegalic patient during combined treatment with pegvisomant and octreotide long-acting repeatable attributed to the use of pegvisomant. Eur. J. Endocrinol. 154, 805-806 (2006).
37. Bonert, v. S. et al. Lipodystrophy in patients with acromegaly receiving pegvisomant. J. Clin. Endocrinol. Metab. 93, 3515-3518 (2008).
38. Maffei, P., Martini, C., Pagano, C., Sicolo, N. & Corbetti, F. Lipohypertrophy in acromegaly induced by the new growth hormone receptor antagonist pegvisomant. Ann. Intern. Med. 145, 310-312 (2006).
39. Hodish, I. & Barkan, A. Long-term effects of pegvisomant in patients with acromegaly. Nat. Clin. Pract. Endocrinol. Metab. 4, 324-332 (2008).